Taylor SE, et al. - Researchers performed this open-label, single-institution, phase II trial, to assess 6-month progression-free survival for everolimus and bevacizumab in patients with recurrent ovarian, peritoneal, and fallopian tube cancer. In addition, the assessment of effectiveness and safety was also performed. In patients, they administered everolimus 10 mg/day by mouth and bevacizumab 10 mg/kg intravenously every 14 days on a 28-day cycle. The patients were treated until disease progression or adverse event. Enrolled patients were 50 in total, with median age of 60.5 years (range 28–82). Measurable disease was present in 46 (92%) individuals. Findings revealed no distinct improvement in response in relation to combining everolimus and bevacizumab vs bevacizumab alone, but benefit may be reported in further investigation of selected patients with changes in the PI3K/mTOR pathway.